Pro-Dex, Inc. (PDEX)
73.41
+11.66
(+18.88%)
USD |
NASDAQ |
Sep 04, 16:00
73.26
-0.15
(-0.20%)
After-Hours: 20:00
Pro-Dex Research and Development Expense (Quarterly) : 1.017M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.017M |
| March 31, 2026 | 0.827M |
| December 31, 2025 | 0.734M |
| September 30, 2025 | 0.768M |
| June 30, 2025 | 0.905M |
| March 31, 2025 | 0.947M |
| December 31, 2024 | 0.942M |
| September 30, 2024 | 0.843M |
| June 30, 2024 | 0.836M |
| March 31, 2024 | 0.76M |
| December 31, 2023 | 0.788M |
| September 30, 2023 | 0.805M |
| June 30, 2023 | 0.695M |
| March 31, 2023 | 0.713M |
| December 31, 2022 | 0.467M |
| September 30, 2022 | 0.929M |
| June 30, 2022 | 0.726M |
| March 31, 2022 | 0.658M |
| December 31, 2021 | 0.615M |
| September 30, 2021 | 0.98M |
| June 30, 2021 | 1.20M |
| March 31, 2021 | 1.104M |
| December 31, 2020 | 0.989M |
| September 30, 2020 | 1.091M |
| June 30, 2020 | 0.815M |
| Date | Value |
|---|---|
| March 31, 2020 | 0.62M |
| December 31, 2019 | 0.397M |
| September 30, 2019 | 0.484M |
| June 30, 2019 | 0.545M |
| March 31, 2019 | 0.603M |
| December 31, 2018 | 0.326M |
| September 30, 2018 | 0.408M |
| June 30, 2018 | 0.448M |
| March 31, 2018 | 0.56M |
| December 31, 2017 | 0.478M |
| September 30, 2017 | 0.407M |
| June 30, 2017 | 0.386M |
| March 31, 2017 | 0.257M |
| December 31, 2016 | 0.278M |
| September 30, 2016 | 0.304M |
| June 30, 2016 | 0.375M |
| March 31, 2016 | 0.301M |
| December 31, 2015 | 0.264M |
| September 30, 2015 | 0.428M |
| June 30, 2015 | 0.359M |
| March 31, 2015 | 0.48M |
| December 31, 2014 | 0.444M |
| September 30, 2014 | 0.384M |
| June 30, 2014 | 0.361M |
| March 31, 2014 | 0.381M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Abbott Laboratories | 892.00M |
| AngioDynamics, Inc. | 8.178M |
| Alphatec Holdings, Inc. | 18.17M |
| AtriCure, Inc. | 25.67M |
| Baxter International, Inc. | 125.00M |